Neutral for Credit
• AstraZeneca have announced that they will upgrade their US listing by replacing ADRs with a full listing on Nasdaq and the NYSE.
• The London listing will continue. Will continue to be in the FTSE 100 and OMX 30 indices.
• "The Board is determined to ensure that the AstraZeneca Group has the flexibility to access the broadest available pool of capital, including in the US, which today's announcement will make possible."
• AZN does not suffer the valuation discount that many UK listed companies suffer vs their US peers. This may be marginally good for the equity but not seismic. No credit implications in the near term and doesn't look like they will do a full delisting in the UK any time soon.
Find more articles and bullets on these widgets:
S&P has upgraded Portugal's long-term credit rating to A+ from A, with a stable outlook (had been positive).
With few market-moving data points this week, implied Fed rate cuts essentially held onto their post-Jackson Hole upward repricing, adding a couple of basis points of easing for good measure heading into the Labor day weekend.


We've just published our latest US Macro Weekly - Download Full Report Here
